Compare TKO & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TKO | LEGN |
|---|---|---|
| Founded | 1980 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5B | 5.9B |
| IPO Year | N/A | 2020 |
| Metric | TKO | LEGN |
|---|---|---|
| Price | $212.12 | $21.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 17 | 13 |
| Target Price | ★ $222.31 | $69.67 |
| AVG Volume (30 Days) | 1.2M | ★ 2.7M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.85 | N/A |
| Revenue | ★ $2,545,175,000.00 | $909,045,000.00 |
| Revenue This Year | $69.99 | $68.83 |
| Revenue Next Year | $29.75 | $51.27 |
| P/E Ratio | $113.56 | ★ N/A |
| Revenue Growth | N/A | ★ 74.75 |
| 52 Week Low | $133.07 | $21.51 |
| 52 Week High | $213.23 | $45.30 |
| Indicator | TKO | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 72.49 | 20.03 |
| Support Level | $201.60 | $26.43 |
| Resistance Level | $209.73 | $28.97 |
| Average True Range (ATR) | 5.83 | 1.25 |
| MACD | 1.70 | -0.41 |
| Stochastic Oscillator | 85.54 | 0.73 |
TKO Group Holdings Inc is a sports and sports entertainment company that operates combat sports and sports entertainment companies. It owns and manages valuable sports and entertainment intellectual property. The company distributes content and monetizes its intellectual property through four principal activities: Media Rights and Content, Live Events, Sponsorship, and Consumer Products Licensing. The company has two reportable segments, UFC and WWE. The company generates majority of revenue from the UFC segment. The UFC segment revenue consists of media rights fees associated with the distribution of its programming content, ticket sales, and site fees associated with the business's international live events, sponsorship, and consumer products licensing agreements of UFC-branded products.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.